Reneuron Group (RENE)
13/11/2017 - 11:30 RNS
RNS Number: 3245W ReNeuron Group plc 13 November 2017 13 November 2017 AIM: RENE ReNeuron Group plc ("ReNeuron" or "the Company") Notification of Interim Results ReNeuron Group plc (AIM: RENE), a UK-based global leader in the development of cell-based therapeutics , intends to announce its interim results for the six months ended 30 Septembe...
08/11/2017 - 09:45 StockMarketWire
ReNeuron Group said its retinal disease clinical trial had moved into its second phase following approval from a data safet...
08/11/2017 - 07:00 RNS
RNS Number: 8587V ReNeuron Group plc 08 November 2017 8 November 2017 AIM: RENE ReNeuron Group plc ("ReNeuron" or the "Company") Retinal disease clinical trial moves into Phase II Data Safety Monitoring Board gives approval for ongoing retinitis pigmentosa clinical trial to progress into Phase II element based on short term safety data ReNeuron Gr...
31/10/2017 - 09:51 StockMarketWire
ReNeuron Group has provided an update on the Phase II clinical trial of its CTX cell therapy candidate for stroke disabilit...
Join interactive investor
- £22.50 fixed quarterly charge includes £22.50 in trading credits
- £10 per trade or £6 for frequent traders
- No % platform fees
- £1 per trade for regular investment or dividend reinvestment